XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.3

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of segment reporting information

Schedule of segment reporting information
		Three Months Ended September 30,
		2025				2024
Total revenues		$	18,149			$	36,031
Less:
Cost of revenues (excluding amortization and depreciation)			3,948				12,694
Research and development expense (excluding share-based compensation expense):
Clinical trials			33,505				50,000
Halo Project			128,935				94,418
Desktop project			11,700				34,147
Other research and development			52,380				-
General and administrative expense and Salaries and benefits (excluding stock based compensation and amortization expense)			779,900				547,606
Amortization			5,473				4,211
Stock based compensation			1,082,790				1,539,169
Professional fees			265,149				262,303
Interest income, net			(2,288	)			(1,000	)
Equity in net (income) loss from equity method investees			-				(159	)
Other income			(67,032	)			(59,101	)
Segment net loss			(2,276,311	)			(2,448,257	)
Reconciliation of net loss
Adjustments and reconciling items			-				-
Consolidated net loss		$	(2,276,311	)		$	(2,448,257	)

		Nine Months Ended September 30,
		2025				2024
Total revenues		$	129,752			$	141,542
Less:
Cost of revenues (excluding amortization and depreciation)			40,344				29,097
Research and development expense (excluding share-based compensation expense):
Clinical trials			235,083				60,825
Halo Project			517,506				316,194
Desktop project			47,113				75,671
Other research and development			58,880				952
General and administrative expense and Salaries and benefits (excluding stock based compensation and amortization expense)			2,089,859				1,787,487
Amortization			15,385				10,666
Stock based compensation			2,291,734				2,008,801
Professional fees			811,562				731,099
Interest income, net			(8,081	)			(1,370	)
Equity in net (income) loss from equity method investees			1,048				(4,651	)
Other income			(125,046	)			(99,322	)
Segment net loss			(5,845,635	)			(4,773,907	)
Reconciliation of net loss
Adjustments and reconciling items			-				-
Consolidated net loss		$	(5,845,635	)		$	(4,773,907	)

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration